Abbott ABT today
announced that the U.S. Food and Drug Administration (FDA) has approved
HUMIRA^® (adalimumab) for inducing and sustaining clinical remission in adult
patients with moderately to severely active ulcerative colitis (UC) when
certain other medicines have not worked well enough. Combined with its
approval to treat moderate to severe Crohn's disease, HUMIRA is now approved
for the treatment of two primary diseases that comprise inflammatory bowel
disease (IBD).
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in